ChemoMetec A/S (0DZ0.L)
| Previous close | 778.50 |
| Open | 791.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 791.00 - 810.50 |
| 52-week range | 304.00 - 905.00 |
| Volume | |
| Avg. volume | 5,187 |
| Market cap | 120.703M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 1.09 |
| EPS (TTM) | 7.55 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireQ3 2023/24 - First sale of the XM30 completed
ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completed Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the year-earlier period. The development reflected continued growth in sales of consumables and services, set off by declining sales of instruments as customers continued to show restraint in purchasing new instruments. EBITDA fell to DKK 43.1 million in the third quarter, being affe
- Globe Newswire
Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million. Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in
- Globe Newswire
Major shareholder announcement – BlackRock, Inc.
ANNOUNCEMENT NO. 260 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 9 April 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of the Capital Markets Act. The
